🇺🇸 Erlotinib [Tarceva] in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pyrexia — 3 reports (23.08%)
  2. Cellulitis — 2 reports (15.38%)
  3. Abdominal Pain Lower — 1 report (7.69%)
  4. Asthenia — 1 report (7.69%)
  5. Bacterial Test Positive — 1 report (7.69%)
  6. Chills — 1 report (7.69%)
  7. Condition Aggravated — 1 report (7.69%)
  8. Conduction Disorder — 1 report (7.69%)
  9. Congestive Cardiomyopathy — 1 report (7.69%)
  10. Cough — 1 report (7.69%)

Source database →

Erlotinib [Tarceva] in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Erlotinib [Tarceva] approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Erlotinib [Tarceva] in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.